Has Matthew McBride, MD received payments from drug or device companies?

Yes. Drug and device makers reported $33,105 in general payments to Matthew McBride, MD across 219 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew McBride, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew McBride, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew McBride, MD

Gastroenterology · Oklahoma City, OKNPI 1871536920

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,583 of the $33,105 with a category attached, or 80.3%. AbbVie accounts for 81.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $12,952 and has fallen 98.6% since, to $180 in 2025. Among gastroenterology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,105in general payments, 2019–2025

Across 219 payments — averaging $151.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$27K
E.r. Squibb & Sons, L.L.C.$3K
Janssen Scientific Affairs, LLC$367
Medtronic$329
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$323
Conmed Corporation$281
plus $1K from 20 others

$707,562in research payments, 2019–2025

Across 282 payments — averaging $2509.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$266K
Takeda Pharmaceuticals U.S.A., Inc.$124K
Shire North American Group Inc$88K
AbbVie$74K
Boehringer Ingelheim$59K
AstraZeneca$54K
plus $43K from 3 others

What the payments were for

Speaking & faculty fees$26,58380%
Travel & lodging$1,2784%
Food & beverage$5,24516%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	116	$26,893
E.r. Squibb & Sons, L.L.C.	2	$3,455
Janssen Scientific Affairs, LLC	3	$367
Medtronic	2	$329
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	23	$323
Conmed Corporation	2	$281
Takeda Pharmaceuticals U.S.A., Inc.	16	$277
Bristol Myers Squibb	2	$171
Phathom Pharmaceuticals, Inc.	3	$146
Micro-tech Endoscopy USA, Inc.	1	$129
Daiichi Sankyo Inc.	6	$110
Gilead	7	$93
Johnson & Johnson	5	$75
Merck	5	$65
Redhill Biopharma Inc.	4	$57
QOL Medical, LLC	3	$46
Pfizer	3	$40
Intercept Pharmaceuticals, Inc.	3	$37
Shire North American Group Inc	2	$37
Mallinckrodt Hospital Products Inc.	2	$30
UCB, Inc.	2	$28
Ironwood Pharmaceuticals, Inc	2	$27
Ardelyx, Inc.	1	$25
Amgen	2	$25
Sanofi	1	$21
Genentech, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Humira$6,105
Skyrizi$5,733
ZEPOSIA$3,572
Rinvoq$3,511
LINZESS$400
STELARA$367
INTERSTIM$329
CONMED BILIARY$281
Lockado$129
CONMED GENERATORS$128
CONMED HEMOSTASIS$128
VOQUEZNA$125

How this compares

$33,105 in reported general payments places this provider in the 90th percentile of 133 gastroenterology providers in Oklahoma.

See all gastroenterology providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$57,394

Medicare patients

313

Services billed

434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	12	$79,382
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	160	$2,809
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl	78	$1,498
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	17	$1,144
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg	19	$551
Omeprazole	37	$512

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Oklahoma City

George SalemOklahoma City$1.2M
Tauseef AliOklahoma City$536K
Pooja SinghalOklahoma City$140K
Hussein BitarOklahoma City$120K
Trushar PatelOklahoma City$49K
Sanjay SikkaOklahoma City$31K
Tony TranOklahoma City$11K
Ahmad Al-TaeeOklahoma City$11K
Sumit WaliaOklahoma City$10K
Kenneth SeresOklahoma City$9K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →